Targeting the glutamatergic system to treat XXXX : current evidence and future perspectives.

@entity1 @entity2227 @entity2682 @entity146 @entity73 @entity4987 @entity898 @entity3393 @entity11532 @entity1771 @entity74 @entity7776 @entity2728 @entity4481 @entity1772 @entity14081
@entity11532 or @entity74 has been defined by the @entity4987 as a behavioral addiction. To date, its pathophysiology is not completely understood and there is no FDA-approved treatment for @entity74 . @entity2227 is the principal excitatory neurotransmitter in the nervous system and it has been recently involved in the pathophysiology of @entity146 . In this paper, we review the current literature on a class of drugs that act as modulating @entity2227 system in PG. A total of 19 studies have been included, according to inclusion and exclusion criteria. Clinical trial and case series using glutamatergic drugs ( @entity898 , @entity3393 , @entity7776 , @entity1771 , @entity14081 , @entity1772 , @entity2682 , @entity4481 , and @entity2728 ) will be presented to elucidate the effectiveness on gambling behaviors and on the related clinical dimensions (craving, withdrawal, and @entity73 ) in PG @entity1 . The results have been discussed to gain more insight in the pathophysiology and treatment of PG. In conclusion, manipulation of glutamatergic neurotransmission appears to be promising in developing improved therapeutic agents for the treatment of @entity74 . Further studies are required. Finally, we propose future directions and challenges in this research area.
